HC Wainwright maintains "buy" rating and $50 target price for Actinium Pharmaceuticals (ATNM).
HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research note. Six brokerages covering the company have an average rating of "Buy", with a consensus 1-year target price of $25.60. Other analysts, such as Cantor Fitzgerald and StockNews.com, have also provided recent reports on the stock.
May 24, 2024
3 Articles